Duopharma Biotech Bhd (7148) - Total Assets
Based on the latest financial reports, Duopharma Biotech Bhd (7148) holds total assets worth RM1.45 Billion MYR (≈ $363.62 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 7148 total equity for net asset value and shareholders' equity analysis.
Duopharma Biotech Bhd - Total Assets Trend (2006–2025)
This chart illustrates how Duopharma Biotech Bhd's total assets have evolved over time, based on quarterly financial data.
Duopharma Biotech Bhd - Asset Composition Analysis
Current Asset Composition (December 2025)
Duopharma Biotech Bhd's total assets of RM1.45 Billion consist of 56.6% current assets and 43.4% non-current assets.
| Asset Category | Amount (MYR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | RM0.00 | 20.1% |
| Accounts Receivable | RM235.37 Million | 16.3% |
| Inventory | RM293.17 Million | 20.2% |
| Property, Plant & Equipment | RM0.00 | 0.0% |
| Intangible Assets | RM0.00 | 0.0% |
| Goodwill | RM0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Duopharma Biotech Bhd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 7148 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Duopharma Biotech Bhd's current assets represent 56.6% of total assets in 2025, a decrease from 64.9% in 2006.
- Cash Position: Cash and equivalents constituted 20.1% of total assets in 2025, down from 34.2% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2006.
- Asset Diversification: The largest asset category is inventory at 20.2% of total assets.
Duopharma Biotech Bhd Competitors by Total Assets
Key competitors of Duopharma Biotech Bhd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.15 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥10.58 Billion |
Duopharma Biotech Bhd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.61 | 4.10 | 2.57 |
| Quick Ratio | 1.68 | 2.70 | 1.68 |
| Cash Ratio | 0.00 | 1.49 | 0.00 |
| Working Capital | RM505.45 Million | RM549.62 Million | RM311.48 Million |
Duopharma Biotech Bhd - Advanced Valuation Insights
This section examines the relationship between Duopharma Biotech Bhd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.69 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | 5.2% |
| Total Assets | RM1.45 Billion |
| Market Capitalization | $309.14 Million USD |
Valuation Analysis
Below Book Valuation: The market values Duopharma Biotech Bhd's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Duopharma Biotech Bhd's assets grew by 5.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Duopharma Biotech Bhd (2006–2025)
The table below shows the annual total assets of Duopharma Biotech Bhd from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | RM1.45 Billion ≈ $363.62 Million |
+5.18% |
| 2024-12-31 | RM1.38 Billion ≈ $345.72 Million |
+2.37% |
| 2023-12-31 | RM1.35 Billion ≈ $337.72 Million |
+10.08% |
| 2022-12-31 | RM1.22 Billion ≈ $306.78 Million |
+4.96% |
| 2021-12-31 | RM1.16 Billion ≈ $292.27 Million |
+9.99% |
| 2020-12-31 | RM1.06 Billion ≈ $265.74 Million |
+15.07% |
| 2019-12-31 | RM919.80 Million ≈ $230.93 Million |
+9.97% |
| 2018-12-31 | RM836.38 Million ≈ $209.99 Million |
+18.59% |
| 2017-12-31 | RM705.24 Million ≈ $177.06 Million |
+6.62% |
| 2016-12-31 | RM661.46 Million ≈ $166.07 Million |
+4.42% |
| 2015-12-31 | RM633.45 Million ≈ $159.04 Million |
+184.72% |
| 2014-12-31 | RM222.48 Million ≈ $55.86 Million |
+8.18% |
| 2013-12-31 | RM205.65 Million ≈ $51.63 Million |
+3.85% |
| 2012-12-31 | RM198.03 Million ≈ $49.72 Million |
+0.26% |
| 2011-12-31 | RM197.52 Million ≈ $49.59 Million |
+0.53% |
| 2010-12-31 | RM196.48 Million ≈ $49.33 Million |
+13.33% |
| 2009-12-31 | RM173.36 Million ≈ $43.53 Million |
+15.28% |
| 2008-12-31 | RM150.38 Million ≈ $37.76 Million |
+18.10% |
| 2007-12-31 | RM127.33 Million ≈ $31.97 Million |
-19.92% |
| 2006-12-31 | RM159.01 Million ≈ $39.92 Million |
-- |
About Duopharma Biotech Bhd
Duopharma Biotech Berhad, an investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally. The company offers consumer healthcare products, such as vitamins, minerals, and supplements, analgesics, eyecare, antacids, and skin care products; and generic drugs for various therapeutic classes, such as ca… Read more